SKSri Krishna

Sri Krishna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sri Krishna has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Selective expansion of neoantigen-specific peripheral blood lymphocytes through antigen-presenting cell-T cell conjugate isolation

    by Mamduh Khateb, Raina Jung, Patrick Hadley, Stav Leibou, Zhiya Yu, Aaron J Dinerman, Victoria Dulemba, Billel Gasmi, Noam Levin, Sanghyun Peter Kim, et al.

    Background Neoantigen-specific peripheral blood lymphocytes (NeoPBL) are the circulating counterparts of neoantigen-specific tumor-infiltrating lymphocytes (TILs). A recent study showed NeoPBL exist in a less differentiated state in vivo than TIL, which, along with their non-invasive potential, makes them attractive for cell therapy. However, NeoPBL circulate at ultra-low frequencies, usually less than 0.005%, posing a major translational barrier for their clinical use.Methods Here, we used NeoSelect, a peptide-based cyclic enrichment and expansion strategy that leverages magnetic selection of antigen-presenting cell-NeoPBL conjugates ex vivo to increase NeoPBL frequency by several thousand-fold over 28 days while also achieving large-scale expansion. We then evaluated expanded cells using functional, transcriptomic, and epigenetic profiling.Results Most NeoPBL clonotypes amplified by NeoSelect are detectable as exhausted TIL in vivo. In addition, neoantigen-specific TIL that failed to expand during ex vivo culture could be recovered as NeoPBL. Transcriptional and epigenetic analyses reveal that ex vivo NeoPBL have distinct transcriptional and epigenetic programs compared with TIL and retain expression of and chromatin accessibility at genes associated with stemness ( TCF7, KLF2) and costimulation (CD28, CD40LG).Conclusions NeoPBL encompass physiologically relevant antitumor clonotypes, can be rapidly expanded to clinically useful numbers and frequencies ex vivo, and can be used to expand the targetable neoantigen repertoire. By combining broad potential applicability and minimal invasiveness, these results position NeoPBL as a clinically streamlined and biologically distinct autologous cell platform that may be useful for adoptive cell transfer.

  • Open Access

    Cell surface ADGRG1 and CD86 expression identifies antitumor CD4 + T cells in human cancer

    by Kyle J. Hitscherich, Aaron J. Dinerman, Abraham A. Hakim, Victoria Dulemba, Sivasish Sindiri, Billel Gasmi, Alakesh Bera, Jared J. Gartner, Todd D. Prickett, Zhiya Yu, et al.

    Adoptive cell transfer of tumor infiltrating CD4 + T cells or T cells genetically modified to express antitumor CD4 + T cell receptors (TCRs) has shown clinical efficacy in patients with advanced solid tumors. We previously defined unique transcriptomic states of antitumor, neoantigen-specific CD8 + and CD4 + tumor infiltrating lymphocytes (TIL) in human cancer. However, optimal cell surface protein markers that identify and would enable viable cell isolation and selective enrichment of antitumor CD4 + T cells have yet to be identified. Here, we define transcriptomic and corresponding cell surface protein profiles of antitumor CD4 + TIL within metastatic colorectal tumors using high dimensional single cell transcriptomic and proteomic analysis. Comprehensive analysis of 45 antitumor CD4 + TCR clonotypes demonstrated uniquely high cell surface protein expression of ADGRG1, CD86, and CD57. In all samples containing tumor neoantigen-reactive CD4 + TIL clonotypes, ADGRG1- and CD86-based cell surface enrichment of known reactive TCR clonotypes were 11-fold and 9-fold higher than bulk CD4 + TIL, respectively. ADGRG1- and CD86-based cell surface enrichment identified >60 validated antitumor CD4 + TCR-clonotypes including tumor organoid-reactive TCRs, as well as neoantigen-specific TCRs targeting private tumor mutations and cancer driver mutations. While both ADGRG1 and CD86 enriched CD4 + TIL displayed an exhausted neoantigen-specific gene expression signature, CD86 also enriched for cytotoxic CD4 + TIL phenotypes. CD4 + TIL isolated based on ADGRG1 expression and expanded in vitro also demonstrated neoantigen reactivity in two samples. Thus, ADGRG1 and CD86 appear to be effective protein markers for isolating human tumor-specific CD4 + TCR clonotypes and studying antitumor CD4 + TIL.

  • Open Access

    Simultaneous gene-engineering of T cells with multiple neoantigen-specific T cell receptors for adoptive cell transfer

    by Melinda Magna, Lior Levy, Krisztian Csomos, Aaron J. Dinerman, Abraham A. Hakim, Noam Levin, Sanghyun P. Kim, Nikolaos Zacharakis, Neilesh Parikh, Brian D. Bui, et al.

  • Hallmarks and correlates of effective adoptive cell immunotherapy for cancer

    by Sri Krishna, Paul F. Robbins, Frank J. Lowery, Steven A. Rosenberg

    Cancer immunotherapies have shown promise and success in a number of different types of tumours, yet many solid epithelial tumours remain recalcitrant. Somatic mutations in tumour cells can lead to the expression of neoantigens, which are potent targets of the human antitumour immune response. These can be targeted through adoptive cell transfer (ACT) of neoantigen-specific T cells, including tumour-infiltrating lymphocytes (TILs) or T cell receptor (TCR)-engineered T cells (TCR-T cells), an approach that has been shown to achieve tumour regression in patients with different types of metastatic solid tumours including melanoma, breast and gastrointestinal cancer. Immunogenomics, systems immunology and genome editing now provide multidisciplinary tools to design cell therapies against solid cancer. Here, we review historical efforts and our current conceptual understanding of ACT using TILs or TCR-T cells. Moreover, we highlight emerging correlates of response to ACT and novel strategies that integrate tumour immunology, cancer genomics, computational biology and T cell engineering for the development of next-generation cellular immunotherapies.


  • Open Access

    Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8⁺ T cells

    by Sri Krishna, Zhiya Yu, Mohona Chakravarti, Victoria Dulemba, Aaron Dinerman, Lior Levy, Kyle Hitscherich, Jared Gartner, Sivasish Sindiri, Kristen Skonieczny, et al.

    Most antitumor CD8 ⁺ T cells in patients exhibit dysfunctional phenotypes, limiting the efficacy of adoptive cell transfer (ACT) against cancer. Although cancer vaccines can induce antitumor stem-like T cell (T SL ) phenotypes, whether they can reverse T cell dysfunction during ACT remains unclear. Using murine neoantigen-specific tumor models, we show that concurrent neoantigen-vaccination enhances the antitumor activity of ACT-products dominated by dysfunctional T cells, relying on host antigen-presenting cells. Vaccination remodels the immunosuppressive tumor microenvironment and promotes the expansion of T SL cells into tumors and lymphoid organs. Mechanistically, vaccination does not directly rescue dysfunctional T cells; but selectively amplifies low-frequency T SL (as low as 0.1% in infusion) to mediate tumor control. Analysis of human dysfunctional TIL-ACT infusion products containing scarce antitumor T SL cells (~1%) administered to a patient with metastatic melanoma corroborated these findings, demonstrating complete clinical tumor regression and expansion of adoptively transferred tumor-specific-TIL clonotypes only after vaccination. These data suggest that concurrent vaccines can unlock the therapeutic potential of rare stem-like T cells within otherwise ineffective dysfunctional ACT.

  • Open Access

    Publisher Correction: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial

    by Frank J. Lowery, Stephanie L. Goff, Billel Gasmi, Maria R. Parkhurst, Nivedita M. Ratnam, Hyunmi K. Halas, Thomas E. Shelton, Michelle M. Langhan, Aarushi Bhasin, Aaron J. Dinerman, et al.


  • Top Cited Papers

    Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial

    by Frank J. Lowery, Stephanie L. Goff, Billel Gasmi, Maria R. Parkhurst, Nivedita M. Ratnam, Hyunmi K. Halas, Thomas E. Shelton, Michelle M. Langhan, Aarushi Bhasin, Aaron J. Dinerman, et al.

    Adoptive transfer of unselected autologous tumor-infiltrating lymphocytes (TILs) has mediated meaningful clinical responses in patients with metastatic melanoma but not in cancers of gastrointestinal epithelial origin. In an evolving single-arm phase 2 trial design, TILs were derived from and administered to 91 patients with treatment-refractory mismatch repair proficient metastatic gastrointestinal cancers in a schema with lymphodepleting chemotherapy and high-dose interleukin-2 (three cohorts of an ongoing trial). The primary endpoint of this study was the objective response rate as measured using Response Evaluation Criteria in Solid Tumors 1.0; safety was a descriptive secondary endpoint. In the pilot phase, no clinical responses were observed in 18 patients to bulk, unselected TILs; however, when TILs were screened and selected for neoantigen recognition (SEL-TIL), three responses were seen in 39 patients (7.7% (95% confidence interval (CI): 2.7–20.3)). Based on the high levels of programmed cell death protein 1 in the infused TILs, pembrolizumab was added to the regimen (SEL-TIL + P), and eight objective responses were seen in 34 patients (23.5% (95% CI: 12.4–40.0)). All patients experienced transient severe hematologic toxicities from chemotherapy. Seven (10%) patients required critical care support. Exploratory analyses for laboratory and clinical correlates of response were performed for the SEL-TIL and SEL-TIL + P treatment arms. Response was associated with recognition of an increased number of targeted neoantigens and an increased number of administered CD4+ neoantigen-reactive TILs. The current strategy (SEL-TIL + P) exceeded the parameters of the trial design for patients with colorectal cancer, and an expansion phase is accruing. These results could potentially provide a cell-based treatment in a population not traditionally expected to respond to immunotherapy. ClinicalTrials.gov identifier: NCT01174121.


  • Top Cited Papers

    Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results

    by Maria Parkhurst, Stephanie L. Goff, Frank J. Lowery, Rachel K. Beyer, Hyunmi Halas, Paul F. Robbins, Todd D. Prickett, Jared J. Gartner, Sivasish Sindiri, Sri Krishna, et al.

    Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors (TCRs) from tumor-infiltrating lymphocytes of patients with metastatic gastrointestinal cancers and incorporated the TCR α and β chains into gamma retroviral vectors. We transduced autologous peripheral blood lymphocytes and adoptively transferred these cells into patients after lymphodepleting chemotherapy. In a phase 2 single-arm study, we treated seven patients with metastatic, mismatch repair-proficient colorectal cancers who had progressive disease following multiple previous therapies. The primary end point of the study was the objective response rate as measured using RECIST 1.1, and the secondary end points were safety and tolerability. There was no prespecified interim analysis defined in this study. Three patients had objective clinical responses by RECIST criteria including regressions of metastases to the liver, lungs and lymph nodes lasting 4 to 7 months. All patients received T cell populations containing ≥50% TCR-transduced cells, and all T cell populations were polyfunctional in that they secreted IFNγ, GM-CSF, IL-2 and granzyme B specifically in response to mutant peptides compared with wild-type counterparts. TCR-transduced cells were detected in the peripheral blood of five patients, including the three responders, at levels ≥10% of CD3+ cells 1 month post-ACT. In one patient who responded to therapy, ~20% of CD3+ peripheral blood lymphocytes expressed transduced TCRs more than 2 years after treatment. This study provides early results suggesting that ACT with T cells genetically modified to express personalized neoantigen-reactive TCRs can be tolerated and can mediate tumor regression in patients with metastatic colorectal cancers. ClinicalTrials.gov registration: NCT03412877.


  • Open Access

    Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes

    by Noam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Zhiya Yu, Sivasish Sindiri, Jared J Gartner, Maria Parkhurst, Sri Krishna, Frank J Lowery, et al.

    Background: Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often rare and exhausted, and ex vivo expansion can further reduce their frequencies. This complicates the identification of neoantigen-reactive T-cell receptors (TCRs) and the development of TIL products with high reactivity for patient treatment. Methods: We tested whether TILs could be in vitro stimulated against neoantigens to achieve selective expansion of neoantigen-reactive TILs. Given their prevalence, mutant p53 or RAS were studied as models of human neoantigens. An in vitro stimulation method, termed “NeoExpand”, was developed to provide neoantigen-specific stimulation to TILs. 25 consecutive patient TILs from tumors harboring p53 or RAS mutations were subjected to NeoExpand. Results: We show that neoantigenic stimulation achieved selective expansion of neoantigen-reactive TILs and broadened the neoantigen-reactive CD4+ and CD8+ TIL clonal repertoire. This allowed the effective isolation of novel neoantigen-reactive TCRs. Out of the 25 consecutive TIL samples, neoantigenic stimulation enabled the identification of 16 unique reactivities and 42 TCRs, while conventional TIL expansion identified 9 reactivities and 14 TCRs. Single-cell transcriptome analysis revealed that neoantigenic stimulation increased neoantigen-reactive TILs with stem-like memory phenotypes expressing IL-7R, CD62L, and KLF2. Furthermore, neoantigenic stimulation improved the in vivo antitumor efficacy of TILs relative to the conventional OKT3-induced rapid TIL expansion in p53-mutated or KRAS-mutated xenograft mouse models. Conclusions: Taken together, neoantigenic stimulation of TILs selectively expands neoantigen-reactive TILs by frequencies and by their clonal repertoire. NeoExpand led to improved phenotypes and functions of neoantigen-reactive TILs. Our data warrant its clinical evaluation. Trial registration number: NCT00068003, NCT01174121, and NCT03412877.


  • Open Access

    Adoptive transfer of T lymphocytes retrovirally transduced to express personalized neoantigen reactive T cell receptors can mediate tumor regression in patients with metastatic colorectal cancer

    by Maria Parkhurst, Stephanie Goff, Frank Lowery, Rachel Beyer, Hyunmi Halas, Paul Robbins, Jared Gartner, Sivasish Sindiri, Sri Krishna, Nikolaos Zacharakis, et al.

    Adoptive cell transfer (ACT) using neoantigen reactive T lymphocytes can mediate cancer regression. Here, we developed methods to isolate unique, personalized, neoantigen reactive T cell receptors (TCRs) from tumor infiltrating lymphocytes (TIL) from patients with metastatic gastrointestinal cancers and incorporate the TCR α and β chains into gamma retroviral vectors. We transduced autologous peripheral blood lymphocytes (PBL) using γ-retroviruses and adoptively transferred those cells into patients after lymphodepleting chemotherapy. We treated 7 patients with metastatic, mismatch-repair proficient colorectal cancers who had progressive disease following multiple prior therapies, and three patients had objective clinical responses by RECIST criteria including regressions of metastases to the liver, lung, and lymph nodes. All patients received T cell populations containing ≥50% TCR transduced cells, and all T cell populations were polyfunctional in that they secreted IFNα, GM-CSF, IL-2, and Granzyme B specifically in response to mutant peptides compared to wild type counterparts. TCR transduced cells were detected in the peripheral blood of 5 patients, including the three responders, at levels ≥10% of CD3+ cells approximately one month post-ACT. In one patient with a partial response to therapy, ~20% of CD3+ PBL expressed transduced TCRs more than two years after treatment. These studies demonstrate that ACT with T cells genetically modified to express personalized neoantigen reactive TCRs is safe and can mediate tumor regression in patients with metastatic solid epithelial cancers.